Doxorubicin HCI盐酸阿霉素;法唯实
Doxorubicin Injection阿霉素注射液
Doxorubicin ADM阿霉素
DOXORUBICIN AUTINEOPLASTIC多柔比星
doxorubicin liposomes阿霉素脂质体
doxorubicin hydrochloride盐酸阿霉素;阿霉素;盐酸多柔吡星
Doxorubicin HCL盐酸阿霉素;盐酸多柔吡星;阿霉素;多柔比星脂质体注射剂
Doxorubicin Intermediates阿霉素中间体
Doxorubicin liposomal阿霉素脂质体
On this basis, the effect of Bmi-1 on doxorubicin sensitivity and mechanism were studied.
在此基础上,研究沉默Bmi-1表达对MCF-7细胞及移植瘤阿霉素敏感性的影响及机制。
With the extension of the indwelling time, the inflammation becomes severe gradually and the thrombosis becomes more and more. The difference for the groups with the injection of doxorubicin and mannitol is of statistic significance(inflammation response p<0.05;thrombosis p<0.05).
3同一组留置不同时间静脉炎症反应和血栓形成情况不同,随着留置时间的延长,静脉炎症反应均逐渐加重,血栓形成的血管数逐渐增多,多柔比星组和甘露醇组差异有显著性意义(炎症反应p<0.05;血栓形成p<0.05)。
参考来源 - 静脉留置针对血管损伤的实验研究OBJECTIVE: Cell protective agent Dexrazoxane has been successfully used prevents or reduces the heart toxicity of doxorubicin. It was synthesised first time in 1976 by Creighton.
目的:细胞保护剂右雷佐生(Dexrazoxane, DEX)是一种手性药物,于1976年Creighton首次合成,已成功地用于预防或降低阿霉素的心脏毒性。
参考来源 - 手性药物右雷佐生合成工艺的改进及质量控制